Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Fink-Neuboeck, N; Lindenmann, J; Porubsky, C; Fediuk, M; Anegg, U; Maier, A; Smolle, J; Lamont, E; Smolle-Juettner, FM.
Hazards of Recurrence, Second Primary, or Other Tumor at Ten Years After Surgery for Non-Small-Cell Lung Cancer.
Clin Lung Cancer. 2020; 21(4):333-340
Web of Science PubMed FullText FullText_MUG


Autor/innen der Med Uni Graz:
Anegg Udo
Fediuk Melanie
Fink-Neuböck Nicole
Lamont Eugenia
Lindenmann Jörg
Maier Alfred
Porubsky Christian
Smolle Josef
Smolle-Juettner Freyja-Maria

Dimensions Citations:

Plum Analytics:
Better treatment options entail the risk of multiple tumors in a patient's lifetime. We studied the incidence, risk factors, and prognostic impact of second primaries and other malignancies in patients with operated non-small-cell lung cancer (NSCLC). We retrospectively analyzed 342 consecutive patients with curatively resected NSCLC between 2003 and 2007. Among the 342 patients analyzed, 172 (50.3%) developed locoregional and/or distant recurrence; 25 (7.3%) had a second primary lung cancer, 97 (28.3%) had 1 or more malignancies other than NSCLC either in their history (n = 61; 17.8%) or following resection (n = 64; 18.7%). One hundred fifteen patients (33.6%) had a malignancy other than primary NSCLC. Eight patients developed both a second primary lung cancer and another malignancy. Older age and lower N-stage were significantly correlated with the occurrence of an additional tumor, as shown by a logistic regression nomogram. Whereas the risk of recurrence decreases over time, the risk of developing a second tumor, particularly a second primary lung cancer, remains high during up to 10 years of follow-up. One hundred seventy patients (49.7%) died of the primary (n = 158; 46.2%) or second primary (n = 12; 3.5%) NSCLC, 23 (6.7%) died of another malignancy, and 66 (19.3%) died due to unrelated causes (overall 10-year survival, 33.3%). Second primary lung cancer or other malignancy occurs in 33% of patients with NSCLC; 26% of patients are affected within 10 years after resection of lung cancer. With curative treatment of secondary tumors, there is no negative influence on long-term prognosis of NSCLC; therefore, follow-up beyond 5 years is strongly advisable. Copyright © 2020 Elsevier Inc. All rights reserved.

Find related publications in this database (Keywords)
Bronchial carcinoma
Long-term follow-up
Other malignancies
© Med Uni Graz Impressum